Study finds link between high insulin doses and cancer

PhD. A study led by Yuanjie Mao, published in JAMA Oncology , looked at the relationship between daily insulin dose and cancer incidence. found that higher insulin doses were positively associated with cancer incidence, and the association was stronger in patients with insulin resistance.

“In patients with type 1 diabetes, our findings suggest that traditional metabolic factors such as obesity (weight as (representative) index), glucose control (represented by hemoglobin A1c), and blood pressure control were not associated with cancer incidence,” Mao said. “However, cancer rates were higher in people taking high doses of insulin. Our findings suggest that clinicians may need to balance potential cancer risks when treating patients with type 1 diabetes with high daily doses of insulin, or may prefer to improve insulin sensitivity rather than simply increasing the insulin dose.”

To conduct this study, Mao collaborated with Dr. Zhong Wenjun. , epidemiologists at Merck Research Laboratories in West Point, Pennsylvania, analyzed more than 50 common risk factors such as smoking, alcohol consumption, exercise, metabolic risk factors, drug use, and family history in 1,303 cancer patients for association with cancer incidence. association. 1 diabetic patient with data collected over 28 years. They obtained data from the Diabetes Control and Complications Trial (DCCT) and its follow-up studies, the Epidemiology of Diabetes Interventions and Complications (EDIC) study at the National Center for Diabetes and Digestive and Kidney Diseases repository, and performed statistical analyses on them. The DCCT was a controlled clinical trial of 1,441 patients with type 1 diabetes who were randomly assigned to receive either usual diabetes care or intensive care to assess whether reducing hyperglycemia would reduce the risk of type 1 diabetes complications.

Mao also found that, when assessed separately, age and sex were associated with cancer incidence, and daily insulin doses were significantly higher than Age is associated with a higher risk of cancer, especially with higher insulin doses.

According to the paper, when daily insulin doses are divided into three groups, low: less than 0.5; medium: greater than or equal to 0.5 or less than 0.8; and high: greater than or equal to 0.8 units/kg/day, the hazard ratio was significantly higher in the high-dose group than in the low-dose group. Cancer rates were 2.11, 2.87, and 2.91 per 1,000 people in the low, medium, and high insulin dose groups, respectively.

He went on to explain specifically that women are at higher risk than men; however, there is currently no Know which risk factors may contribute to increased cancer rates in people with type 1 diabetes.

“We know that people with type 1 diabetes are more likely to develop cancer than people without diabetes high,” said Dr. Liz Beverly. said the co-director of the Diabetes Institute and a professor at the School of Heritage. “Dr Mao’s research identifies potential mechanisms explaining this association. His findings will lead to continued research in the field and potential policy changes in cancer screening and insulin dosing recommendations.”

While previous studies have concluded that people with diabetes have an overall higher risk of cancer, this is the first study to explore the incidence of cancer associated with type 1 diabetes. factor research.

“Type 1 diabetes is estimated to account for 5% to 10% of all diabetes cases, a recent study of type 1 diabetes Diabetes has also found higher rates of certain cancers in the population compared to the general population, such as gastric, liver, pancreatic, endometrial and kidney cancers,” Mao explained. “However, in type 2 diabetes, the increased risk is attributable to metabolic factors such as obesity, chronic inflammatory states and insulin resistance.”

While the findings suggest that higher insulin doses were associated with higher rates of cancer, Mao said further research is needed.

Mao graduated from Peking University with a Doctor of Medicine degree. and received residency training in internal medicine at the Akron Clinic in Cleveland and fellow training in endocrinology, diabetes and metabolism at the University of Arkansas. He has since served as a clinical assistant professor in the Department of Specialty Medicine and the Diabetes Research Institute at Ohio University. He also works at Ohio Health as an endocrinologist at the Castrop Center and O’Bryce Hospital. His expertise is diabetes, thyroid disease, osteoporosis and other endocrine diseases. In addition to current research, he is working on several other clinical trials on obesity, type 1 diabetes and type 2 diabetes.